BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 16267271)

  • 21. Plasminogen activator inhibitor 1 functions as a urokinase response modifier at the level of cell signaling and thereby promotes MCF-7 cell growth.
    Webb DJ; Thomas KS; Gonias SL
    J Cell Biol; 2001 Feb; 152(4):741-52. PubMed ID: 11266465
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Signaling through urokinase and urokinase receptor in lung cancer cells requires interactions with beta1 integrins.
    Tang CH; Hill ML; Brumwell AN; Chapman HA; Wei Y
    J Cell Sci; 2008 Nov; 121(Pt 22):3747-56. PubMed ID: 18940913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The inhibitory effect of HKa in endothelial cell tube formation is mediated by disrupting the uPA-uPAR complex and inhibiting its signaling and internalization.
    Liu Y; Cao DJ; Sainz IM; Guo YL; Colman RW
    Am J Physiol Cell Physiol; 2008 Jul; 295(1):C257-67. PubMed ID: 18495808
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Induction of cell migration by pro-urokinase binding to its receptor: possible mechanism for signal transduction in human epithelial cells.
    Busso N; Masur SK; Lazega D; Waxman S; Ossowski L
    J Cell Biol; 1994 Jul; 126(1):259-70. PubMed ID: 7517943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and alpha v beta 5 integrin.
    Franco P; Vocca I; Carriero MV; Alfano D; Cito L; Longanesi-Cattani I; Grieco P; Ossowski L; Stoppelli MP
    J Cell Sci; 2006 Aug; 119(Pt 16):3424-34. PubMed ID: 16882693
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination.
    Festuccia C; Angelucci A; Gravina GL; Biordi L; Millimaggi D; Muzi P; Vicentini C; Bologna M
    Thromb Haemost; 2005 May; 93(5):964-75. PubMed ID: 15886816
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Suppression of urokinase plasminogen activator receptor inhibits proliferation and migration of pancreatic adenocarcinoma cells via regulation of ERK/p38 signaling.
    Xue A; Xue M; Jackson C; Smith RC
    Int J Biochem Cell Biol; 2009; 41(8-9):1731-8. PubMed ID: 19433314
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urokinase plasminogen activator receptor promotes macrophage infiltration into the vascular wall of ApoE deficient mice.
    Gu JM; Johns A; Morser J; Dole WP; Greaves DR; Deng GG
    J Cell Physiol; 2005 Jul; 204(1):73-82. PubMed ID: 15573379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor dormancy induced by downregulation of urokinase receptor in human carcinoma involves integrin and MAPK signaling.
    Aguirre Ghiso JA; Kovalski K; Ossowski L
    J Cell Biol; 1999 Oct; 147(1):89-104. PubMed ID: 10508858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
    Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
    ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration.
    Pluskota E; Soloviev DA; Plow EF
    Blood; 2003 Feb; 101(4):1582-90. PubMed ID: 12393547
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor.
    Hillig T; Engelholm LH; Ingvarsen S; Madsen DH; Gårdsvoll H; Larsen JK; Ploug M; Danø K; Kjøller L; Behrendt N
    J Biol Chem; 2008 May; 283(22):15217-23. PubMed ID: 18362146
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Regulation of alpha5beta1 integrin conformation and function by urokinase receptor binding.
    Wei Y; Czekay RP; Robillard L; Kugler MC; Zhang F; Kim KK; Xiong JP; Humphries MJ; Chapman HA
    J Cell Biol; 2005 Jan; 168(3):501-11. PubMed ID: 15684035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The fibrinolytic receptor for urokinase activates the G protein-coupled chemotactic receptor FPRL1/LXA4R.
    Resnati M; Pallavicini I; Wang JM; Oppenheim J; Serhan CN; Romano M; Blasi F
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1359-64. PubMed ID: 11818541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A competitive chromogenic assay to study the functional interaction of urokinase-type plasminogen activator with its receptor.
    Rettenberger P; Wilhelm O; Oi H; Weidle UH; Goretzki L; Koppitz M; Lottspeich F; König B; Pessara U; Kramer MD
    Biol Chem Hoppe Seyler; 1995 Oct; 376(10):587-94. PubMed ID: 8590627
    [TBL] [Abstract][Full Text] [Related]  

  • 36. uPAR-uPA-PAI-1 interactions and signaling: a vascular biologist's view.
    Binder BR; Mihaly J; Prager GW
    Thromb Haemost; 2007 Mar; 97(3):336-42. PubMed ID: 17334498
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
    Ahmed N; Riley C; Oliva K; Rice G; Quinn M
    Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR.
    Plesner T; Behrendt N; Ploug M
    Stem Cells; 1997; 15(6):398-408. PubMed ID: 9402652
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect.
    Resnati M; Guttinger M; Valcamonica S; Sidenius N; Blasi F; Fazioli F
    EMBO J; 1996 Apr; 15(7):1572-82. PubMed ID: 8612581
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor - β1 (TGF-β1) and potential effects on migration and invasion.
    Magnussen SN; Hadler-Olsen E; Costea DE; Berg E; Jacobsen CC; Mortensen B; Salo T; Martinez-Zubiaurre I; Winberg JO; Uhlin-Hansen L; Svineng G
    BMC Cancer; 2017 May; 17(1):350. PubMed ID: 28526008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.